Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
The Pharma Data
APRIL 14, 2021
Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. Genentech, a member of the Roche group, and Novartis Pharmaceuticals Corporation work together to develop and co-promote Xolair. indications.
Let's personalize your content